ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1776

Macrophage Migration Inhibitory Factor May Help Maintain Tight Junctions in the Gut by Enhancing Occludin Expression

Shaghayegh Foroozan1 and Nigil Haroon2, 1University Health Network/University of Toronto, Toronto, ON, Canada, 2University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, Toronto, ON, Canada

Meeting: ACR Convergence 2023

Keywords: Inflammation, Mouse Models, Other, neutrophils, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1776–1795) Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory disease with multifactorial origins, primarily affecting the musculoskeletal system. Gut inflammation is seen in the majority of AxSpA patients, with 60% having microscopic changes and 10% with overt Inflammatory Bowel Disease (IBD). Over the years many pathways and cell populations have been linked to the pathogenesis of gut inflammation in AxSpA. Macrophage migration inhibitory factor (MIF) plays a critical role in the pathogenesis of AxSpA. Over-expression of MIF in a mouse model of SpA (SKG mice) causes major clinical features of AxSpA while blocking or depletion of MIF significantly suppresses these symptoms. However, the role of MIF in gut inflammation in AxSpA is unknown. We hypothesized that MIF is a key player driving gut inflammation in AxSPA.
To study the effect of MIF on gut homeostasis and inflammation in the SKG mouse model of spondyloarthritis

Methods: A total of 12 SKG control mice, 11 SKG mice treated with curdlan, 9 SKG-MIF Knock Out (KO), and 6 SKG-MIFKO mice treated with curdlan that were all 16 weeks old were used for this study. H&E slides were prepared for histopathology assessment on formalin-fixed paraffin-embedded (FFPE) blocks of ileum tissue (2 individuals scored the samples independently and were blinded to the group). Immunohistochemistry (IHC) was performed for occludin and MPO antibody was used to assess neutrophil (a major source of MIF) infiltration. Kruskal–Wallis test was used to analyze the difference between the 4 groups.

Results: We observed significantly increased inflammation levels in the ileum of SKG+curdlan mice compared to SKG control mice (Fig1a). SKG-MIFKO+curdlan mice did not have a significant benefit of reduction in inflammation levels. Interestingly, even without curdlan treatment, MIFKO mice showed inflammation in the gut. SKG-MIFKO mice (with and without curdlan) developed a disruption of ileal epithelium. There was a significant reduction in occludin expression compared to SKG control mice, suggesting a disruption of tight junctions (Fig1b). MPO expression was significantly elevated in SKG+curdlan and SKG-MIFKO+curdlan groups. However, although not significant, it seems that the MPO expression is lower in the SKG-MIFKO+curdlan compared to SKG+curdlan mice.

Conclusion: Knocking out MIF in SKG mice has shown improvement in AxSpA symptoms. However, based on our findings, MIF seems to have a protective role in the gut of SKG mice unlike what we see in joints. The absence of MIF leads to decreased expression of occludin. These findings together suggest that MIF is essential for the integrity of the gut epithelial barrier in the SKG mouse model of SpA. If this effect on the tight junction is directly related to MIF or through changes in type 3 immune response needs to be investigated.

Supporting image 1


Disclosures: S. Foroozan: None; N. Haroon: AbbVie, 2, Eli Lilly, 2, Janssen, 2, Novartis, 2, UCB Pharma, 2.

To cite this abstract in AMA style:

Foroozan S, Haroon N. Macrophage Migration Inhibitory Factor May Help Maintain Tight Junctions in the Gut by Enhancing Occludin Expression [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/macrophage-migration-inhibitory-factor-may-help-maintain-tight-junctions-in-the-gut-by-enhancing-occludin-expression/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/macrophage-migration-inhibitory-factor-may-help-maintain-tight-junctions-in-the-gut-by-enhancing-occludin-expression/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology